TRANSFORMING CLINICAL CARE: IMPACT OF LEUKAEMIA FOUNDATION’S RESEARCH FUNDING INTO BLOOD CANCER
With
Bill Stavreski, Head of Research
Leukaemia Foundation, Australia
RESEARCH IMPACT
Filmed in Melbourne | May 2025
Released to coincide with World Blood Cancer Day 2025
The Leukaemia Foundation is committed to funding research innovations that drive advancements in new diagnostics, treatments and novel therapies, supporting the careers of promising scientists and clinicians and giving Australians access to global clinical trials.
The Leukaemia Foundation state there are over 120 different types of blood cancer and all of which the Foundation provides support to people.
Bill Stavreski is the Head of Research at the Leukaemia Foundation who talks about the research impact in recent years. The Foundation itself marks its 25th anniversary in 2025, having funded a wide range of health and medical research since 2000. With a focus on basic science, health services research, treatment, and care, the organisation has invested nearly $90 million (adjusted in current dollars terms) in approximately 370 research grants over the years.
The Foundation primarily relies on the generosity of public donations, with no government funding. This funding has led to significant advancements in clinical practice, including a groundbreaking diagnostic test now available across Australia, significantly easing the financial burden on patients.
One notable achievement includes the first successful growth of leukaemic cells in a dish, facilitating advancements in treatment testing. Additionally, the Foundation established a pioneering genomic screening program for patients with hard-to-treat blood cancers, significantly improving the chances of finding effective treatments.
Through this work, the Foundation underscores that research is centred on people, aiming to transform lives and support families affected by blood cancer.
Source: Adapted from the Leukaemia Foundation website and transcript
You Might also like
-
Stem cell therapies for enteric neuropathies
Dr Stamp is a Group Leader in the Department of Anatomy and Physiology at the University of Melbourne, Australia. Dr Stamp’s PhD research (with Prof Martin Pera, Monash University) focused on the derivation of hepatopancreatic progenitors from human embryonic stem cells. He then joined the lab of Dr Don Newgreen at the Murdoch Childrens Research Institute where he began working on development of the enteric nervous system (ENS), before joining Prof Heather Young’s lab at the University of Melbourne, where he focused on developing a stem cell therapy to treat gut motility disorders such as the paediatric enteric neuropathy Hirschprung disease.
-
Genetics of the choroid and impact on eye health
Professor Daniel Fatovich is a senior emergency physician and clinical researcher at Royal Perth Hospital Emergency Department (ED), with over 30 years’ experience in the design and conduct of clinical research in Emergency Medicine. He is also Head of the Centre for Clinical Research in Emergency Medicine (CCREM) within the Harry Perkins Institute of Medical Research.
-
Benefits of prehabilitation ahead of surgery
Dr Matthew Wallen PhD, AES, AEP is a Senior Research Fellow in Cancer Survivorship, the Deputy Lead of the Cancer Survivorship Program, and a Senior Lecturer in Exercise Science and Clinical Exercise Physiology within the College of Nursing and Health Sciences at Flinders University, in South Australia. His clinical interest focuses on improving outcomes for people requiring major surgery, specifically (1) lifestyle interventions, including exercise, nutritional, and psychological support to improve the health and wellbeing of people prior to surgery, termed ‘prehabilitation’, (2) novel physical function assessments aimed at identifying people at risk of treatment-related complications, and (3) implementation of new models of care in cancer.